| lncRNA name in article | Virus & Strain Name | Dosage & Time point | Cell line | Experiment Type | Fold change | Expression | P-value | Differential expression quantification method | Statistical method | Year | PubMed ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CFLAR-AS1 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 0.2 ;
24 hr |
A-549 Human adenocarcinomic alveolar basal epithelial cells (ACE2+) | RNA-Seq | 3.132468496 | Upregulation | 0 | student's t test | 2020 | 32416070 | |
| CFLAR-AS1 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
A-549 Human adenocarcinomic alveolar basal epithelial cells (ACE2+) | RNA-Seq | 4.460682106 | Upregulation | 0 | student's t test | 2020 | 32416070 | |
| CFLAR-AS1 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
Calu-3 Human adenocarcinomic lung epithelialcells | RNA-Seq | 2.257240281 | Upregulation | 3.04E-08 | student's t test | 2020 | 32416070 |
* MOI :Multiplicity of infection , TCID :Tissue Culture Infectious Dose